Clinical trials
Neck Pain trials in Pakistan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
168 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 7 |
| 2020 | 13 |
| 2021 | 31 |
| 2022 | 19 |
| 2023 | 26 |
| 2024 | 19 |
| 2025 | 28 |
| 2026 | 20 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 114 |
| Unknown status | 25 |
| Recruiting | 17 |
| Not yet recruiting | 8 |
| Active, not recruiting | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Riphah International University | 108 |
| Foundation University Islamabad | 13 |
| University of Lahore | 11 |
| Dow University of Health Sciences | 4 |
| Superior University | 4 |
| Elite College of Management Sciences, Gujranwala, Pakistan | 3 |
| University of Faisalabad | 3 |
| Green International University | 2 |
| Ibadat International University, Islamabad | 2 |
| Lahore University of Biological and Applied Sciences | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neck Pain | 168 |
| Pain | 19 |
| Post-Traumatic Headache | 6 |
| Kinesiophobia | 5 |
| Radiculopathy | 5 |
| Myofascial Pain Syndromes | 4 |
| Chronic Pain | 3 |
| Headache | 3 |
| Shoulder Pain | 3 |
| Muscle Weakness | 2 |
Trials
Showing 51 to 75 of 168. Each trial links to its page on Pharma Observatory.
68 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.